Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-pre-clinical-milestone-as-part-of-its-endometriosis-alliance-with-bayer-5460
Evotec to attend three upcoming investor conferences
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at upcoming investor conferences Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-attend-three-upcoming-investor-conferences-5458
Evotec announces first quarter results 2017 and corporate update
Evotec AG today reported financial results and corporate updates for the first quarter of 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-first-quarter-results-2017-and-corporate-update-5456
Evotec achieves first milestone in Diabetes alliance with Sanofi
Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-first-milestone-in-diabetes-alliance-with-sanofi-5452
Evotec´s partner Forge Therapeutics receives prestigious Carb-X research award
Evotec AG today announced that its partner Forge Therapeutics („Forge“) has received a research award from CARB-X (Combating Antibiotic Resistant Bacteria) of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-forge-therapeutics-receives-prestigious-carb-x-research-award-5450
Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery
Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fiscal-year-results-2016-leading-innovation-efficiency–first-in-class-drug-discovery-5448
Great story – Short film
Evotec AG and Business France today released their short film about Evotec’s research site in Toulouse, France, under the headline: “Evotec found Business in France – Great story, short film”. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/great-story—short-film-5441
Evotec AG: 'LAB282' awarded first projects
Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-lab282-awarded-first-projects-5440
Ad hoc: Novo A/S becomes new long-term strategic shareholder in Evotec
Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-novo-as-becomes-new-long-term-strategic-shareholder-in-evotec-5438
Novo A/S becomes new long-term strategic shareholder in Evotec
Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the independent holding company for the Novo Group. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/novo-as-becomes-new-long-term-strategic-shareholder-in-evotec-5630